EPH receptor Inhibitors
1 drugsAbout EPH receptor
EPH receptors are a family of receptor tyrosine kinases involved in cell communication, influencing cell migration, adhesion, and differentiation. They play crucial roles in processes like cell migration, adhesion, and differentiation. These receptors are activated by ephrin ligands.
EPH receptors are attractive therapeutic targets due to their involvement in fundamental cellular processes. Currently, there is no genetic evidence directly linking EPH receptors to specific diseases, limiting confidence in target validation.
There is one FDA-approved drug, CAPRELSA (vandetanib), targeting EPH receptors, developed by Sanofi. CAPRELSA is a small molecule with an 'Other' therapeutic area classification, suggesting niche applications.
Top EPH receptor Drugs
Sanofi is the only company with an approved drug targeting EPH receptors.
Low competition represents an opportunity for new entrants, but also indicates potential challenges in market development.
EPH receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets EPH receptor, using small molecule modality.
Explore alternative modalities like antibodies or PROTACs to differentiate from existing therapies and expand market potential.
EPH receptor Clinical Trials 52 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on EPH receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 23 | 14 | 9 | 0 | 61% |
| Phase 2 | 24 | 15 | 7 | 2 | 68% |
| Phase 3 | 4 | 2 | 1 | 1 | 67% |
| Phase 4 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
EPH receptor Drug Approval Timeline (2011 - 2011)
The first and only drug, CAPRELSA, was approved in 2011.
The lack of recent approvals suggests a saturated market or challenges in developing new EPH receptor-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 32 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on EPH receptor. A trial counts if an approved drug acting on EPH receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.